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Background: 
Bone cancer pain has a disruptive effect on the cancer patient’s quality of life. Although ginsenosides have 
been used as traditional medicine in Eastern Medicine, the effect on bone cancer pain has not been thoroughly 
studied. The aim of this study was to determine whether ginsenosides may alter the bone cancer pain at the 
spinal level. 
Methods: 
NCTC 2472 tumor cells (2.5 × 10
5) were injected into the femur of adult male C3H/HeJ mice to evoke 
bone tumor and bone cancer pain. To develop bone tumor, radiologic pictures were obtained. To assess pain, 
the withdrawal threshold was measured by applying a von Frey filament to the tumor cells inoculation site. 
The effect of intrathecal ginsenosides was investigated. Effect of ginsenosides (150, 500, 1,000 μg) was 
examined at 15, 30, 60, 90, 120 min after intrathecal delivery.
Results: 
The intrafemoral injection of NCTC 2472 tumor cells induced a radiological bone tumor. The withdrawal 
threshold with tumor development was significantly decreased compared to the sham animals. Intrathecal 
ginsenosides effectively increased the withdrawal threshold in the bone cancer site. 
Conclusions: 
NCTC 2472 tumor cells injection into the mice femur caused bone tumor and bone cancer pain. Intrathecal 
ginsenosides attenuated the bone cancer-related pain behavior. Therefore, spinal ginsenosides may be an 
alternative analgesic for treating bone cancer pain. (Korean  J  Pain  2010;  23:  230-235)
Key  Words:
antinociception, bone cancer pain, ginsenosides, mice, spinal cord.MH Yoon, et al / Intrathecal and Bone Cancer Pain 231
INTRODUCTION
    Early cancer diagnosis and v arious therapeutic options 
have  extended  the  life  expectancy  of  cancer  patients. 
Unfortunately, however pain management for patients with 
malignant disease has not been effective, which decreased 
the  quality  of  life  of  cancer  patients.  Approximately, 
20-50% of all cancer patients suffer pain and 75-90% of 
terminal cancer patients experience severe pain [1]. The 
m os t diffi c u l t t ype o f can cer pain is bo n e c an cer pain, 
which occurs primarily in bone or secondarily by meta-
stasis from distant organs to bones [2-4]. The character-
is tics of bone can cer pain ar e cons tan t, in cr eased with 
time and exacerbated after movement or weight-bearing 
on the affected limb [5-7]. The most commonly used an-
algesics for cancer pain control are non-steroidal anti-in-
flammatory drugs (NSAIDs) and opiates [8]. However, de-
spite the widespread use of both drugs, their analgesic ef-
fect is often limited and they sometimes cause side effects 
[ 9 , 1 0 ] .  T h e r e f o r e ,  t h e  e f f e c t i v e  a n d  s a f e  a n a l g e s i c s  f o r  
cancer pain management are needed.
    The root of Pannax ginseng C.A. Meyer, or ginseng, 
has been used as an herbal medicine [11]. Therefore, it has 
been used for a long time to relieve some types of pain 
such as toothaches, abdominal pain and neuralgia in tradi-
tional folk medicine. The major active constituents of gin-
seng are ginsenosides [12]. It has been reported that gin-
senosides inhibited postoperative pain and inflammatory 
pain at the spinal level of rats [13-15]. Therefore, we hy-
pothesized  that  spinal  ginsenosides  may  reduce  cancer 
pain. 
    The aim of this study was to evaluate the efficacy of 
an intrathecal ginsenosides in a murine bone cancer pain 
model.
MATERIALS  AND  METHODS
    All procedures were performed following the approval 
b y th e Ins tit u ti o n a l An im a l Car e an d U se Co m m i ttee o f 
Chonnam National University. The experiments were done 
on a d u l t m a l e C3H/H eJ m i ce, w e ighing 20-25 g. Th ese 
strains were selected for their histocompatibility with the 
NCTC 2472 tumor line [American T ype Culture Collection 
(A TCC), Rockville, MD, USA]. The mice were housed in a 
vivarium, maintained at 22 ± 0.5
oC with a 12-h light/dark 
cycle and were allowed to access food and water.
    T umor cells were incubated and cultured in NCTC 135 
medium (Sigma-Aldrich Co., St. Louis, MO, USA) with 10% 
horse serum (ATCC) at 37
oC in a 5% CO2 in air atmosphere, 
and passed two to three times weekly. T umor cells in-
oculated into the femur of the mice under intraperitoneal 
ketamine (100 mg/kg) anesthesia according to a previously 
described method [16]. When the mice did not respond to 
a paw pinch, the right thigh of the mice was shaved and 
disinfected with povidone-iodine. A 1 cm skin incision was 
made along the lateral femur and a 25 gauge needle was 
inserted  into  the  medullary  cavity  of  the  distal  femur. 
Tumor cells were injected using a hand-driven, gear-op-
erated  injector  connected  to  the  25-gauge  needle  with 
polyethylene-10 tube. Twenty μl of minimal essential me-
dium (MEM) alone (sham; n = 3) or MEM containing 2.5 
× 10
5 tumor cells (n = 6) were injected slowly. The in-
jection site was sealed with dental amalgam, and the skin 
was closed with 6-0 silk sutures. Radiographics and the 
d e t e r m i n a t i o n  o f  t h e  w i t h d r a w a l  t h r e s h o l d  i n  t u m o r  
cells-injected femur were done at 7, 14, 21 days after tu-
mor cells inoculation to assess the bone tumor and bone 
cancer pain development.
    Ginsenosides were used in this study and provided by 
the Korea Ginseng and Tobacco Research Institute (Daejon, 
Korea) and dissolved in dimethylsulfoxide (DMSO). Ginse-
nosides were intrathecally administered according to the 
procedure of Hylden and Wilcox [17] using a 25 μl Hamilton 
syringe with a 30-gauge needle. The needle was inserted 
between L5 and L6 and the injection volume was 5 μl. The 
intrathecal placement of a needle was confirmed by ob-
servation of a tail flick of the mice.
    The development of bone cancer pain was evaluated 
by  measuring  the  mechanical  sensitivity  of  the  tumor 
cells-injected femur. The withdrawal threshold in response 
to mechanical stimulation was measured with von Frey fil-
aments (Stoelting, Wood Dale, IL, USA). One of von Frey 
filaments (0.4-3.6 g) was applied to the tumor cells-in-
jected femur for 4 s while the filament was bent. Sharp 
withdrawal or flinching of paw was regarded as a positive 
response. If no response was noted at a pressure of 3.6 
g, mice were assigned to this cutoff value. The 50% paw 
withdrawal threshold was determined according to a pre-
vious method of Dixon [18]. 
    F ourteen days after tumor cells inoculation, the be-
havioral study was commenced. The mice were placed in-
dividually in plastic cages with a plastic mesh floor (4 × 232 Korean J Pain Vol. 23, No. 4, 2010
Fig. 1. Radiographics of sham-injected (A) and NCTC 2472 tumor cells-injected mice. Tumor cells were inoculated into 
the femur and radiological examination was done at 14 (B) and 21 (C) days after tumor cells injection. Tumor cells injections
induced bone tumor and osteolysis over time. No change was seen in sham group. Arrows head indicated the bone destruction.
Fig. 2. Time course of the withdrawal response to von Frey
filaments after tumor cells injection. Each line represents 
mean ± SEM of 4−6 mice. B = baseline withdrawal 
threshold measured before tumor cells injection. Paw 
withdrawal threshold (g) was plotted versus time in days. 
A significant difference was noted between the tumor and 
sham groups. *P  ＜ 0.05.
5 × 5 cm) and allowed to adapt for 20-30 min before the 
experiments. Intrathecal ginsenosides (150, 500, 1,000 μg, 
n = 19) were administered and the withdrawal threshold 
was measured at 15, 30, 60, 90, and 120 min after delivery 
of ginsenosides. Intrathecal DMSO was used as a control 
(n = 3). The withdrawal threshold measured before tumor 
cells  injection  was  regarded  as  the  baseline  threshold. 
Each mouse was tested only once. The investigator was 
blind to the experimental conditions in all cases. 
    T o examine the abnormal behaviors of ginsenosides, 
additional naive rats (n = 5) were given intrathecal ginse-
nosides (1,000 μg), and examined at 15, 30, 60, 90, and 
120  min  after  administration.  The  righting  and  plac-
ing-stepping reflexes were checked for evaluation of motor 
function. The first was tested by placing the mice prone 
on the table, which normal mice immediately take a pos-
ture to an upright position. The latter was tested by plac-
ing the dorsum of hind paw across the edge of the table, 
which normal mice put their paws forward into a position 
for walking. Next, pinna and corneal reflexes were eval-
uated with a paper string [19]. The first was tested by 
stimulation of the ear canal, which normal mice sponta-
neously shake their heads. The latter was tested by stim-
ulation of the cornea, which normal mice spontaneously 
blink. All of four reflexes were judged as present or absent. 
    The data are expressed as mean ± SEM. The time- 
response data are presented as the withdrawal threshold 
in g. The dose-response data are presented as percentage 
of maximal possible effect (%MPE) according to the formula. 
         Postdrug threshold - baseline threshold
%MPE =                                           × 100%
        Cut-off threshold (3.6) - baseline threshold
    The dose-response data were analyzed using one-way 
a n a l y s i s  o f  v a r i a n c e  ( A N O V A ) .  D i f f e r e n c e s  i n  t h e  w i t h-
drawal threshold between the sham and tumor mice were 
analyzed using unpaired t-tests. Results were statistically 
significant in case of P ＜ 0.05.
RESULTS
    NCTC 2472 tumor cells inoculation into the intra-
medullary cavity of distal femur of mice radiographically 
induced bone destruction over time (Fig. 1). However, the 
bone tumor was not noted in MEM-injected femur (sham) 
until 21 days after injection. The inoculation of tumor cells 
into the femur resulted in a decrease of the withdrawal 
threshold in injected site (Fig. 2). By contrast, no change 
of the withdrawal threshold was noted in mice with sham 
injection.
    Intrathecal administration of ginsenosides dose-de-
pendently increased the withdrawal threshold in mice with MH Yoon, et al / Intrathecal and Bone Cancer Pain 233
Fig. 3. Effects of intrathecal ginsenosides on the withdrawal response to von Frey filaments after tumor cells injection.
The data are presented as the withdrawal threshold (A) or percent of the maximum possible effect (%MPE, B). Each line
or bar represents mean ± SEM of 5−6 mice. B = baseline withdrawal threshold measured before tumor cells injection.
DMSO = dimethylsulfoxide. The withdrawal threshold was measured immediately before ginsenosides delivery, and 
intrathecal ginsenosides were administered at time 0 (arrow). The withdrawal threshold was dose-dependently increased
with ginsenosides. *P < 0.05, 
†P ＜ 0.01.
tumor cells inoculation (Fig. 3). At 150 μg, intrathecal gin-
senosides did not affect the withdrawal threshold. At 500 
μg, ginsenosides increased the withdrawal threshold, how-
ever, the effect was progressively declined. At 1,000 μg, 
the eff ect w as main tained d uring the en tire observ ation 
period.
    After the intrathecal delivery of ginsenosides, the 
righting, placing-stepping, the pinna and corneal reflexes 
were present.
DISCUSSION
    In the present study, we ev aluated the analgesic eff ect 
of ginsenosides in bone cancer pain model. The injection 
of NCTC 2472 tumor cells into the femur resulted in an 
osteolysis and decreased the withdrawal threshold in tumor 
cells-injected site. These observations indicated that the 
intrafemoral injection of NCTC 2472 tumor cells may prop-
erly induce bone tumor and bone cancer pain model as re-
ported previously [16]. 
    T o date, NSAIDs and opiates have been considered as 
typical analgesics for bone cancer pain [8]. However, de-
spite a variety of pharmacotherapies for bone cancer pain, 
the effect is relatively poor. Such difficulty of treatment 
is caused by a lack of knowledge of the basic neurobiology 
of bone cancer pain. But, the use of the mouse bone can-
c e r  m o d e l  u s e d  i n  t h i s  s t u d y  m a y  e x p e d i t e  t h e  u n d e r-
standing of the pathophysiology of bone cancer pain and 
advance the development of novel analgesics for treating 
bone cancer pain. 
    In this study, intrathecal ginsenosides produced a 
d o s e- d e p e n d e n t  in c r ea s e o f t h e  w i t h d r a w a l t hr es h o l d  i n 
the bone cancer site. Furthermore, the antinociceptive ef-
fect was persistent during the observation period at the 
highest dose. These findings suggest that ginsenosides are 
active against bone tumor pain at the spinal level. Ginseng 
has long been used in Eastern Medicine medicine to im-
prove the weakened physical status brought on by stress 
or disease [11]. Ginsenosides, ginseng saponins, are the 
major components responsible for the effects of ginseng 
[20]. Previous experiments also suggest that ginsenosides 
are effective to a variety of nociceptive conditions. Intra-
thecal  ginsenosides  inhibit  formalin-induced,  substance 
P-induced and paw incision-induced pain behaviors in an-
imals [13-15]. These observations, thus suggest that gin-
seng m a y aff or d an an tin oci ce p ti v e a c ti o n in th e s pin a l 
cord. 
    In spite of the wide use of ginsenosides in a various 
medical  fields,  the  mechanism  of  action  remains  to  be 
determined.  Chemically,  ginsenosides  have  a  four-ring, 
s t e r o i d - l i k e  s t r u c t u r e  w i t h  s u g a r  m o i e t i e s  a t t a c h e d  a n d 
show properties similar to acetylcholine, adrenaline, and 234 Korean J Pain Vol. 23, No. 4, 2010
histamine [21], which suggests that these chemicals may 
b e  i n v o l v e d  i n  t h e  a c t i o n  m e c h a n i s m  o f  g i n s e n o s i d e s .  
Furthermore, recently it has been reported that opioid re-
ceptors may play an important role in the antinociceptive 
mechanism of action of ginsenosides at the spinal level 
[14]. Previous studies have also shown that the nicotinic 
acetylcholine receptor may contribute to the mechanism of 
action of ginsenosides [15,22]. Moreover, several lines of 
e vid en ce sugges t that Ca
2＋ c hanne ls p la y an im portan t 
role in the pharmacological activity of ginsenosides [23-25]. 
On the other hand, it has been reported that alpha2, mus-
carinic, and GABA receptors are not the pharmacological 
sites of action of ginsenosides [23,26].
    There were some limitations in this study. First, the 
au th ors on l y e v a lu ated th e e ff ect of ginsen osid es. Mor e 
researches with different types of chemicals may be need-
ed for the determination of the mechanism of action of 
ginsenosides. Second, the authors just used the behavioral 
stud y. Mo lec ular works ma y he lp to examine the a ction 
mechanism of ginsenosides. 
    Spinal ginsenosides are not yet available clinically. 
H o w e v e r ,  g i n s e n o s i d e s  m a y  b e  u s e d  e f f e c t i v e l y  i n  t h e  
management of bone cancer pain in the future. Thus, this 
is the first report which proposed the possibility for clinical 
use of ginsenosides.
    T aken together, injection of NCTC 2472 tumor cells 
i n t o  t h e  f e m u r  o f  m i c e  c a u s e d  b o n e  t u m o r  a n d  p a i n .  
Intrathecal ginsenosides dose-dependently attenuated the 
bone cancer pain. Therefore, spinal ginsenosides may be 
useful for managing bone cancer pain.
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